The price debate around weight-loss drugs has a policy question behind it

A 2025 health-economics analysis put a number on a growing policy question: how the price of widely used weight-loss medicines compares with the health benefits modeled for them. The analysis examined Wegovy and Zepbound using a common cost-effectiveness measure.

The issue reaches beyond a list price. Employers, insurers and public programs face recurring spending decisions while patients can encounter very different coverage rules and out-of-pocket costs. Those choices help determine whether an approved medicine is financially reachable, not whether it is right for any one person.

The analysis was a model, not a coverage order or clinical recommendation. Its conclusions depend on assumptions about price and long-term outcomes, and it cannot settle whether future savings will offset current spending.

Read the full story at The New York Times ↗